Author: admin

Laser Capture Microdissection Market worth $306 million by 2029 | MarketsandMarkets™

“Laser Capture Microdissection Market in terms of revenue was estimated to be worth $184 million in 2024 and is poised to reach $306 million by 2029, growing at a CAGR of 10.6% from 2024 to 2029 according to a new report by MarketsandMarkets™”
Browse 139 market data Tables and 40 Figures spread through 193 Pages and in-depth TOC on “Laser Capture Microdissection Market by Product (Instruments, Consumables, Software, Services), System Type (Ultraviolet, Infrared, Immunofluorescence), Application (R&D (Molecular Biology, Cell Biology, Forensics), Diagnostics) – Global Forecast to 2029

 Laser Capture Microdissection Market in terms of revenue was estimated to be worth $184 million in 2024 and is poised to reach $306 million by 2029, growing at a CAGR of 10.6% from 2024 to 2029 according to a new report by MarketsandMarkets™. The growth of this market is driven by increasing demand of laser capture microdissection in cancer research, collaborations between academic institutions, research organizations, and industry players to develop innovative LCM technologies. Additionally, continuous advancements in laser technology, microscopy, and automation have led to improved precision, efficiency, and ease of use of LCM systems.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=140404059

The consumables segment accounted for the largest share, by product in the laser capture microdissection market in 2023.

By product, the laser capture microdissection market has been further categorized as instruments, consumables, software and services. The consumables segment held the largest share of the global laser capture microdissection market in 2023. This can be attributed to increasing adoption of LCM technology across various research fields, advancements in sample preparation techniques, and the rising demand for personalized medicine. Furthermore, support from government agencies and funding organizations for research initiatives in areas such as cancer, neuroscience, and precision medicine provides financial resources for the procurement of LCM consumables. Government funding drives research activities and accelerates the adoption of LCM technology, thereby stimulating the demand for consumables.

The research and development segment accounted for the largest share of the application segment in the laser capture microdissection market in 2023.

Based on application, the global laser capture microdissection market has been segmented into research & development, diagnostics, and other applications. The research & development segment held the largest market share in 2023. The large share of this segment can be attributed to the use of laser capture microdissection for gene expression analysis has lent itself to a diverse set of research areas and applications, including cancer biology, cell biology, neurobiology, pathology, neuroscience, and developmental biology.

The North America region catered the largest share of the laser capture microdissection market in 2023.

The laser capture microdissection market in North America has experienced significant growth in recent years, showcasing a robust expansion trajectory, owing to large pharmaceutical & biopharmaceutical industry in the region, the rising R&D expenditure, stringent regulations, and the presence of major providers of laser capture microdissection products in the US and Canada. Additionally, growth of the North American laser capture microdissection market is driven by significant factors such as a multitude of ongoing cancer research and clinical trials, the expansion of the biosimilars and generics sector, and the increasing adoption of outsourcing preclinical, clinical, and laboratory testing services by pharmaceutical and biopharmaceutical companies.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=140404059

Laser Capture Microdissection Market Dynamics:

Drivers:

1.  Increase in R&D funding

Restraints:

1.  Requirement of high degree of technical expertise

Opportunities:

1.  Integration with omics technologies

Challenge:

1.  Time-consuming sample preparation process

Key Market Players of Laser Capture Microdissection Industry:

Key players in the laser capture microdissection market include Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Carl Zeiss AG (Germany), F. Hoffmann-La Roche AG (Switzerland), Standard BioTools (US), JSR Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Bruker (US), Molecular Machines & Industries GmbH (Germany), Ocimum Biosolutions (US), Theralink Technologies, Inc. (US), 3DHISTECH, Ltd. (Hungary), Creative Biolabs (US), DeNova Sciences (Singapore), Laxco, Inc. (US), CaresBio Laboratory LLC (US), VitroVivo Biotech (US), AnaPath Services GmbH (Switzerland), Gnome Diagnostics & Gnome Sciences (US), Monasterium Laboratory (Germany), Independent Forensics (US), Norgen Biotek Corp. (Canada), Creative Bioarray (US), and Epistem Ltd. (UK).

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 60% and Demand Side 40%
  • By Designation: C-level – 50%, D-level – 20%, and Others – 30%
  • By Region: North America -40%, Europe -40%, and Asia-Pacific -20%

Recent Developments of Laser Capture Microdissection Industry:

  • In August 2023, Danaher Corporation (US) acquired Abcam plc (UK), a leading supplier of protein consumables. Abcam is to operate as a standalone operating company and brand within Danaher’s Life Sciences segment, furthering Danaher’s strategy to help map complex diseases and accelerate the drug discovery process using Danaher’s technology.
  • In March 2023, Crown Bioscience International (US), a JSR Life Sciences Company, acquired a 100.0% stake in Indivumed Services GmbH& Co. KG (Germany) to further accelerate drug discovery and create solutions to meet customer needs by bringing a variety of synergistic service platforms to Crown Bioscience’s drug discovery and development services.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=140404059

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/laser-capture-microdissection-market-140404059.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Laser Capture Microdissection Market worth $306 million by 2029 | MarketsandMarkets™

Medical Robots Market worth $33.8 billion by 2029

“Prominent players in the medical robots market include Intuitive Surgical, Inc. (US), Stryker Corporation (US), Medtronic Plc (US), Smith & Nephew Plc (UK), Zimmer Biomet Holdings, Inc. (US), Asensus Surgical, Inc.(US), Zap Surgical Systems, Inc.(US), Renishaw Plc (UK)”
North America accounted for the largest share of the medical robots market. As this region is home to a significant number of medical robots manufacturers.

 Medical Robots Market in terms of revenue was estimated to be worth $16.0 billion in 2024 and is poised to reach $33.8 billion by 2029, growing at a CAGR of 16.1% from 2024 to 2029 according to a new report by MarketsandMarkets™. The growth in the medical robots market is driven by the aging population and rising chronic diseases, improving reimbursement scenario, and subsequent advancements in healthcare funding & infrastructure. The adoption of medical robots is also expected to increase with the increasing need for automation in healthcare. However, the high cost of robotic systems may pose a challenge to the medical robots market during the forecast period.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=2916860

Soft tissue surgical robotic system is the fastest growing in the medical robots market in 2023.

Based on type, the medical robots market is segmented into surgical robotic system, rehabilitation robotic systems, radiosurgery robotic systems, and hospital & pharmacy robotic systems. The surgical robotic systems have been further segmented into surgical robotic systems by application – soft tissue surgical robotic system (general surgery, gynecological surgery, urological surgery, and other applications) and hard tissue surgical robotic system (knee & hip surgery and spine surgery). The rehabilitation robotic systems have been further segmented into rehabilitation robotic systems by type – therapeutic robotic systems, assistive robotic systems, exoskeleton robotic systems, and other rehabilitation robotic systems. The hospital & pharmacy robotic systems have been further segmented into – pharmacy robotic systems (robotic dispensing systems, compounding robotic systems, and other pharmacy robotic systems) and hospital robotic systems (delivery robotic systems, telepresence robotic systems, diagnostic robotic systems, and other hospital robotic systems).

The soft tissue surgical robotic system sub-segment is the fastest growing surgical robotic system in the medical robots market in 2023, attributing to the increasing prevalence of various conditions such as cancer, appendicitis, obesity, and others. These conditions lead to increased demand for robot-assisted surgical procedures with higher accuracy.

Instruments & accessories are the largest product of the medical robots market in 2023.

Based on products & services, the medical robots market is segmented into robotic systems, instruments & accessories, and services. Among these, instruments and accessories segment accounted for the largest share of the medical robots market in 2023. The recurrent purchase of instruments & accessories to be used with the robotic systems instead of robotic systems leads to the higher adoption of this segment.

By end user, ambulatory surgery centers is the fastest growing in the medical robots market in 2023.

Based on end user, the medical robots market is segmented into hospitals & clinics, ambulatory surgery centers, pharmacies, rehabilitation centers, and other end users. The ambulatory surgery centers segment is expected to be the fastest growing segment of the market.  The surgical procedures being offered by ASCs at a lower cost than hospitals drives the higher adoption of ambulatory surgery centers among patients.

North America dominates the global medical robots market in 2023.

The medical robots market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. In 2023, North America accounted for the largest share of the medical robots market. As this region is home to a significant number of medical robots manufacturers. Moreover, the increasing adoption of robotic systems by hospitals in the country, the increasing volume of robotic-assisted surgical procedures, and the favourable reimbursement policies in the region, reinforces its position at the forefront of the medical robots market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=2916860

Medical Robots Market Dynamics:

Drivers:

  1. Growing need to minimize medication errors

Restraints:

  1. High cost of robotic systems

Opportunities:

  1. Growth opportunities in emerging markets

Challenge:

  1. Patient and provider acceptance

Key Market Players of Medical Robots Industry:

Prominent players in the medical robots market include Intuitive Surgical, Inc. (US), Stryker Corporation (US), Medtronic Plc (US), Smith & Nephew Plc (UK), Zimmer Biomet Holdings, Inc. (US), Asensus Surgical, Inc.(US), Zap Surgical Systems, Inc.(US), Renishaw Plc (UK), Hocoma Ag (Switzerland), Accuray Incorporated (US), Elekta (Sweden), Becton, Dickinson And Company (US), Omnicell, Inc. (US), Arxium (Canada), Ekso Bionics Holdings, Inc. (US), Bionik Laboratories Corp. (US), Lifeward, Inc. (Israel), Cyberdyne Inc.(Japan), Avateramedical Gmbh (Germany),Johnson & Johnson (US), and Swisslog Healthcare (Switzerland).

Breakdown of the supply-side, demand side, primary interviews by company type, designation, and region:

  • By Supply Side: Tier 1 (25%), Tier 2 (5%), and Tier 3 (70%)
  • By Designation: C-level Executives (27%), Director-level (18%), and Others (55%)
  • By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%), and Middle East and Africa (5%)

Recent Developments of Medical Robots Industry:

  • In April 2023, Intuitive Surgical’s da Vinci SP system received US FD for a simple prostatectomy.
  • In November 2022, an Indian startup SS Innovations launched SSI Mantra for soft tissue surgeries.
  • In July 2022, Becton, Dickinson & Company (US) acquired Parata Systems (US) to provide portfolio of innovative pharmacy automation solutions to reduce costs, enhance patient safety and improve the patient experience for retail, hospital and long-term care pharmacies.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=2916860

Medical Robots Market – Key Benefits of Buying the Report:

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:

  • Analysis of key drivers (aging population and rising chronic diseases, technological advancements, increasing need for automation in healthcare, improving reimbursement scenario, and advancements in healthcare funding & infrastructure, and growing need to minimize medication errors), restraints (high cost of robotic systems and stringent regulatory requirements), opportunities (growth opportunities in emerging markets, and novel application) and challenge (patient and provider acceptance).
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the medical robots market.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of medical robots solutions across regions.
  • Market Diversification: Exhaustive information about solutions, untapped regions, recent developments, and investments in the medical robots market.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the medical robots market.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/medical-robotic-systems-market-2916860.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Medical Robots Market worth $33.8 billion by 2029

X-Ray Detectors Market worth $4.2 billion by 2029

“prominent players in the X-ray detectors market are Varex Imaging Corporation (US), Thales Group( France), Canon( Japan), Fujifilm Corporation (Japan), Agfa-Gevaert Group (Belgium) and Teledyne Technologies(US), and among others.”
The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall x-ray detectors market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies.

X-Ray Detectors Market in terms of revenue was estimated to be worth $3.1 billion in 2023 and is poised to reach $4.2 billion by 2029, growing at a CAGR of 5.0% from 2023 to 2029 according to a new report by MarketsandMarkets™. The market is experiencing growth driven by increased investments in the enhancement of healthcare facilities and digital imaging technologies. The demand for early diagnosis is on the rise, leading to an expanded scope of clinical applications for X-ray detectors. Additionally, the prevalence of chronic disorders requiring prompt examinations is increasing, compounded by the growing trend of sedentary lifestyles.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=7004984

 

The Flat-panel detectors segment is to register significant growth rate over the forecast period of 2023-2029.

Based on the technology, the global X-Ray Detectors Market is categorized based on technology, including Flat Panel Detectors, Computed Radiography Detectors, Line-Scan Detectors, and Charged Coupled Detectors. The flat-panel detector segment is anticipated to experience the most significant growth rate during the forecast period. Computed Radiography detectors hold the second-largest share in the X-Ray detectors market.

The medical applications segment accounted for the largest share of the x-ray detectors market, by application in 2023.

Based on application, the X-ray detectors market is divided into various segments, including medical applications, dental applications, security/defence applications, veterinary applications, industrial applications, and other applications. In 2024, the medical applications segment held the largest market share and is projected to exhibit the highest CAGR throughout the forecast period. This dominance is attributed to factors such as the increasing incidence of disorders requiring pre-diagnostic screening and notable advancements in medical technology, both contributing significantly to the substantial share in this category.

The Asia Pacific market to register the highest growth in the market during the forecast period

Based on region, Asia Pacific X-Ray Detectors Market is anticipated to register the highest growth from 2023 to 2029. Major players in the market are focusing on expanding their manufacturing capabilities in the APAC. The region is witnessing a consistent rise in the uptake of advanced equipment. Significant growth prospects for key players are being fueled by improvements in healthcare systems and government initiatives focused on the modernization of healthcare infrastructure.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=7004984

X-Ray Detectors Market Dynamics:

Drivers:

  1. Investment to advance healthcare facilities & digital imaging Technologies

Restraints:

  1. High cost of X-ray detectors

Opportunities:

  1. Rising healthcare expenditure across developing countries

Challenge:

  1. Lack of animal awareness in emerging and developing countries

Key Market Players of X-Ray Detectors Industry:

As of 2022, prominent players in the X-ray detectors market are Varex Imaging Corporation (US), Thales Group( France), Canon( Japan), Fujifilm Corporation (Japan), Agfa-Gevaert Group (Belgium) and Teledyne Technologies(US), and among others.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3–16%
  • By Designation: Director-level– 14%, C-level–10%, and Others–76%
  • By Region: North America– 40%, Europe– 32%, Asia Pacific–20%, Latin America-5%, Middle East and Africa-3%

Recent Developments of X-Ray Detectors Industry:

  • In May 2023, Varex Imaging Corporation launched the XRD 3131N digital X-ray detector to cater to the rising demand for expedited and more extensive inspections within the rapidly evolving Electric Vehicle (EV) battery manufacturing sector. This enhances the company’s existing portfolio for the EV battery inspection market.
  • In July 2022, Canon Inc. launched the CXDI-Elite series of wireless digital radiography (DR2) devices, including the CXDI-720C Wireless sensor unit, to markets outside of Japan. These devices aim to enhance user-friendliness across various imaging scenarios while delivering superior image quality to facilitate more accurate diagnostics.
  • March 2021, At ECF 2021, the Thales unveiled the Pixium 3040F, featuring enhanced image quality, optimized spatial resolution, increased contrast, and superior sensitivity at lower radiation doses.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=7004984

X-Ray Detectors Market – Key Benefits of Buying the Report:

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall x-ray detectors market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/x-ray-detectors-market-7004984.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: X-Ray Detectors Market worth $4.2 billion by 2029

Gene Expression Analysis Market worth $6.2 billion by 2029 | MarketsandMarkets™

“The North American region is observing rising investments in the field of drug discovery & development. Moreover, the need for advanced therapies due to the rising rate of chronic diseases such as cancer has contributed to the growth of the gene expression analysis market.”
Browse 436 market data Tables and 54 Figures spread through 369 Pages and in-depth TOC on “Gene Expression Analysis Market by Product (Reagents, Enzymes, kits, DNA Chips, PCR, NGS, DNA Microarray), Service (RNA Sequencing, Bioinformatics), Application (Drug discovery & development, clinical diagnostics), End User – Global Forecast to 2029

 Gene Expression Analysis Market in terms of revenue was estimated to be worth $4.2 billion in 2024 and is poised to reach $6.2 billion by 2029, growing at a CAGR of 8.1% from 2024 to 2029 according to a new report by MarketsandMarkets™. The gene expression analysis market is experiencing significant growth due to several key factors. Firstly, the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is driving the demand for advanced diagnostic and therapeutic solutions. Gene expression analysis plays a crucial role in understanding the genetic basis of these diseases, enabling personalized medicine approaches for more effective treatments. However, the high cost of instruments & consumables and concerns associated with data privacy and security are expected to restrain the market growth during the forecast period.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=156613968

The assays & kits segment accounted for the largest share of reagents & consumables in the gene expression analysis market in 2023.

By reagents & consumables, the gene expression analysis market has been further categorized into assays & kits, enzymes, DNA chips, and others. Assays & kits accounted for the largest share of the gene expression analysis market in 2023. The increasing adoption of high-throughput technologies such as next-generation sequencing (NGS) and microarray analysis has boosted the demand for assays and kits. These technologies generate large amounts of data, and assays and kits help in streamlining the workflow, from sample preparation to data analysis.

The drug discovery & development application segment is expected to grow at a higher rate during the forecast period. 

Based on technology, the gene expression analysis market has been segmented into drug discovery & development, clinical diagnostics, and other applications. In 2023, the drug discovery & development segment accounted for the largest share of the gene expression analysis market and is expected to grow at a higher growth rate during the forecast period of 2024-2029. The share share of drug discovery & development application is attributed to gene expression analysis is instrumental in the preclinical and clinical stages of drug development. In preclinical studies, researchers use gene expression profiling to assess the efficacy and safety of potential drug candidates. This helps in selecting the most promising candidates for further development, reducing the time and cost associated with drug discovery.

The pharmaceutical & biotechnology companies segment accounted for the largest share of the end user segment in the gene expression analysis market in 2023.

Based on end user, the gene expression analysis market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2023, pharmaceutical & biotechnology companies accounted for the largest share of the gene expression analysis market. As the pharmaceutical & biotechnology companies heavily rely on understanding how genes are expressed in various disease states to identify potential drug targets. Gene expression analysis helps in pinpointing genes that are upregulated or downregulated in diseases, providing valuable insights into disease mechanisms and potential therapeutic interventions.

The North America region accounted for the largest share of the gene expression analysis market in 2023.

The gene expression analysis market is segmented into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. The North American region is observing rising investments in the field of drug discovery & development. Moreover, the need for advanced therapies due to the rising rate of chronic diseases such as cancer has contributed to the growth of the gene expression analysis market. The supportive government regulations in North America for the development of mAbs and biosimilars also contribute to market growth.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=156613968

Gene Expression Analysis Market Dynamics:

Drivers:

1.  Advancements in gene editing technologies

2.  Increasing funding initiatives for genomic research

3.  Growing preference for therapeutic applications

4.  Declining costs of sequencing technologies

Restraints:

1.  High cost of instruments & consumables

2.  Concerns associated with data privacy and security

Opportunities:

1.  High growth potential across non-clinical applications

2.  Machine learning and AI

3.  Growing focus on single-cell analysis

Challenge:

1.  Extensive timelines for product approval

2.  Data interpretation challenges

Key Market Players of Gene Expression Analysis Industry:

Key players in the gene expression analysis market are Thermo Fisher Scientific Inc (US), Bio-Rad Laboratories Inc. (US), Illumina Inc (US), QIAGEN (Netherlands), F. Hoffmann-La Roche (Switzerland), Revvity (US), PacBio (US), Agilent Technologies Inc (US), Oxford Gene Technology IP Limited (UK), BGI (China), Eurofins Scientific (Luxembourg), Standard BioTools (US), Oxford Nanopore Technologies plc (UK), GenScript (US), Takara Bio Inc (Japan), 10x Genomics (US), Zymo Research Corporation (US), Twist Bioscience (US), Promega Corporation (US), LGC Limited (UK), CD Genomics (US), NanoString Technologies Inc. (US), BioSpyder, Inc (US), Integrated DNA Technologies, Inc (US) and New England Biolabs (US).

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side 30%
  • By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives- 25%
  • By Region: North America -45%, Europe -20%, Asia-Pacific -20%, Latin America -10%, Middle East & Africa- 5%

Recent Developments of Gene Expression Analysis Industry:

  • In May 2023, Thermo Fisher Scientific and Pfizer collaborated to expand localized access to Next-generation Sequencing-based testing for cancer patients in over 30 countries across Latin America, Africa, the Middle East, and Asia.
  • In August 2022, Bio-Rad Laboratories Inc. acquired Curiosity Diagnostics to expand its capabilities by inculcating a new generation of rapid PCR systems into its product portfolio.
  • In April 2022, Illumina established a new state-of-the-art facility solution center in São Paulo, Brazil, to expand global access to genomics in Latin America. Illumina’s revenue is majorly generated from markets across North America, Europe, the Middle East, and Africa.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=156613968

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/gene-expression-analysis-market-156613968.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gene Expression Analysis Market worth $6.2 billion by 2029 | MarketsandMarkets™

Advanced Hepatocellular Carcinoma Pipeline 2024 | CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene

DelveInsight’s, “Advanced Hepatocellular Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Hepatocellular Carcinoma pipeline landscape. It covers the Advanced Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Advanced Hepatocellular Carcinoma Research. Learn more about our innovative pipeline today! @ Advanced Hepatocellular Carcinoma Pipeline Outlook

Key Takeaways from the Advanced Hepatocellular Carcinoma Pipeline Report

  • July 2024:- Hoffmann-La Roche- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma. The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC).
  • July 2024:- AbbVie- A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment.
  • DelveInsight’s Advanced Hepatocellular Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Hepatocellular Carcinoma treatment.
  • The leading Advanced Hepatocellular Carcinoma Companies such as CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics, and others.
  • Promising Advanced Hepatocellular Carcinoma Therapies such as Tremelimumab, Durvalumab, Bevacizumab, Livmoniplimab, GT90001, Ori-C101, IBI310, Sintilimab, Sorafenib, and others.

Learn more about Advanced Hepatocellular Carcinoma Drugs Opportunities in our groundbreaking Advanced Hepatocellular Carcinoma Research and development projects @ Advanced Hepatocellular Carcinoma Unmet Needs

Advanced Hepatocellular Carcinoma Emerging Drugs

Tivozanib : AVEO Oncology

FOTIVDA® (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. Tivozanib has been shown to significantly reduce regulatory T-cell production in preclinical models. Currently, Tivozanib is being evaluated in Phase I/II stage of clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.

Nofazinlimab: CStone Pharmaceuticals

CS1003 is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) being developed for immunotherapy of various tumors. Compared to most of the monoclonal antibodies that bind human and monkey PD-1(either already approved or in clinical stage) , CS1003 demonstrates comparable high binding affinities across species against human, cynomolgus monkey and mouse PD-1, and is developed to disrupt the interaction of PD-1 with its ligands PD-L1 and PD-L2 . CS1003 is also unique in that it can simultaneously recognize human and mouse PD-1, which allows fast pre-clinical proof of concept for CS1003 in combination with novel targeted therapies using syngeneic mouse tumor models. Currently, the drug is being developed in Phase III stage of development for the treatment of advanced hepatocellular carcinoma.

ECT 204: Eureka Therapeutics

ECT204, a GPC3 targeting ARTEMIS® T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer. Glypican 3 (GPC3) is a promising target for HCC therapies and is found in more than 70% of HCC cells. The GPC3 protein is also expressed in other solid tumors including ovarian and lung cancer. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.

Sintilimab: Eli Lilly and Company/Innovent

Sintilimab is an immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. Innovent is currently conducting more than 20 clinical studies of sintilimab worldwide, to evaluate its safety and efficacy in a wide variety of cancer indications, including more than 10 registrational or pivotal clinical trials. Sintilimab, marketed as TYVYT® (sintilimab injection) in China, is an innovative PD-1 inhibitor with global quality standards jointly developed by Innovent and Eli Lilly and Company. Currently, the drug is being developed in Phase I stage of Clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.

Learn more about Advanced Hepatocellular Carcinoma Drugs Opportunities in our groundbreaking Advanced Hepatocellular Carcinoma Research and development projects @ Advanced Hepatocellular Carcinoma Unmet Needs

Advanced Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Advanced Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Discover the latest advancements in Advanced Hepatocellular Carcinoma Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Advanced Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Advanced Hepatocellular Carcinoma Pipeline Report

  • Coverage- Global
  • Advanced Hepatocellular Carcinoma Companies- CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics, and others.
  • Advanced Hepatocellular Carcinoma Therapies- Tremelimumab, Durvalumab, Bevacizumab, Livmoniplimab, GT90001, Ori-C101, IBI310, Sintilimab, Sorafenib, and others.
  • Advanced Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Advanced Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Hepatocellular Carcinoma Pipeline on our website @ Advanced Hepatocellular Carcinoma Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Hepatocellular Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Hepatocellular Carcinoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. Drug name: Company Name
  9. Drug profiles in the detailed report…..
  10. Last Stage Products (Phase III)
  11. Nofazinlimab: CStone Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (Phase I/II)
  14. Tivozanib : AVEO Oncology
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Advanced Hepatocellular Carcinoma Key Companies
  21. Advanced Hepatocellular Carcinoma Key Products
  22. Advanced Hepatocellular Carcinoma – Unmet Needs
  23. Advanced Hepatocellular Carcinoma – Market Drivers and Barriers
  24. Advanced Hepatocellular Carcinoma – Future Perspectives and Conclusion
  25. Advanced Hepatocellular Carcinoma Analyst Views
  26. Advanced Hepatocellular Carcinoma Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Hepatocellular Carcinoma Pipeline 2024 | CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene

Basal Cell Carcinoma Pipeline 2024 | PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma

DelveInsight’s, “Basal Cell Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Basal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Basal Cell Carcinoma Research. Learn more about our innovative pipeline today! @ Basal Cell Carcinoma Pipeline Outlook

Key Takeaways from the Basal Cell Carcinoma Pipeline Report

  • July 2024:- Sol-Gel Technologies, Ltd.- A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Gel 2% for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Gorlin Syndrome. The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use.
  • June 2024:- Biofrontera Bioscience GmbH- The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) with the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for superficial basal cell carcinoma (BCC).
  • DelveInsight’s Basal Cell Carcinoma Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Basal Cell Carcinoma treatment.
  • The leading Basal Cell Carcinoma Companies such as PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, and others.
  • Promising Basal Cell Carcinoma Therapies such as BO-112, SP-002, Vismodegib, Nivolumab, Ipilimumab, Relatlimab, Vismodegib, and others.

Stay informed about the cutting-edge advancements in Basal Cell Carcinoma treatments. Download for updates and be a part of the revolution in cancer care @ Basal Cell Carcinoma Clinical Trials Assessment

Basal Cell Carcinoma Emerging Drugs

  • Patidegib: PellePharm

Patidegib is an investigational small molecule that inhibits hedgehog signaling. It is a topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib is currently evaluated in Phase III clinical trials for the treatment of BCCs.

  • AIV001: AiViva BioPharma

AIV001 is a novel formulation of a multi-kinase inhibitor combined with AiViva’s proprietary delivery technology, designed for prolonged drug release via intradermal treatment. AIV001 targets multiple pathways to reduce fibroplasia in overlapping phases of wound healing and scarring; targets VEGFR to limit the inflammation and fibrosis associated with rosacea; and inhibits or reduces neovascularization and cell proliferation associated with certain cancers. AIV001 is in Phase I/II clinical studies for the treatment of patients with Basal Cell Carcinoma.

Learn more about Basal Cell Carcinoma Drugs Opportunities in our groundbreaking Basal Cell Carcinoma Research and development projects @ Basal Cell Carcinoma Unmet Needs

Basal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Basal Cell Carcinoma Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Discover the latest advancements in Basal Cell Carcinoma treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Basal Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Basal Cell Carcinoma Pipeline Report

  • Coverage- Global
  • Basal Cell Carcinoma Companies- PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, and others.
  • Basal Cell Carcinoma Therapies- BO-112, SP-002, Vismodegib, Nivolumab, Ipilimumab, Relatlimab, Vismodegib, and others.
  • Basal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Basal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Basal Cell Carcinoma Pipeline on our website @ Basal Cell Carcinoma Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Basal Cell Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Basal Cell Carcinoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Patidegib: PellePharm
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. IO103: IO Biotech
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. AIV001: AiViva BioPharma
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Cannabidiol: Leaf Vertical
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Basal Cell Carcinoma Key Companies
  21. Basal Cell Carcinoma Key Products
  22. Basal Cell Carcinoma- Unmet Needs
  23. Basal Cell Carcinoma- Market Drivers and Barriers
  24. Basal Cell Carcinoma- Future Perspectives and Conclusion
  25. Basal Cell Carcinoma Analyst Views
  26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Basal Cell Carcinoma Pipeline 2024 | PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma

Tareen Dermatology Featured in Online Article Highlighting Advanced Dermatopathology Techniques

Tareen Dermatology Featured in Online Article Highlighting Advanced Dermatopathology Techniques

Tareen Dermatology, Roseville, MN, USA
Tareen Dermatology, a leader in comprehensive skin care, is proud to announce that it has been featured in an insightful online article titled “The Science Behind Skincare:

Tareen Dermatology, a leader in comprehensive skin care, is proud to announce that it has been featured in an insightful online article titled “The Science Behind Skincare: How Tareen Dermatology Utilizes Advanced Dermatopathology for Precise Diagnoses.” The article details the innovative approaches employed by Tareen Dermatology to ensure accurate diagnoses and optimal patient outcomes through advanced dermatopathology.

Understanding Dermatopathology

The article begins by explaining the importance of dermatopathology, the study of skin diseases at a microscopic level, and its crucial role in the accurate diagnosis and treatment of various skin conditions. It elaborates on how dermatopathologists at Tareen Dermatology analyze skin biopsies to diagnose conditions ranging from benign issues like psoriasis to more serious diseases such as melanoma.

Advanced Techniques in Dermatopathology

Highlighting Tareen Dermatology’s commitment to cutting-edge technology, the article describes several advanced techniques employed by the clinic:

  • Histopathology: The cornerstone of dermatopathology, involving the examination of stained tissue sections to observe the architecture and cellular details of the skin.

  • Molecular Dermatopathology: Integrating molecular biology with traditional histopathology to detect genetic mutations and chromosomal abnormalities, particularly useful in diagnosing conditions like melanoma.

How Tareen Dermatology Utilizes Dermatopathology

The article also covers Tareen Dermatology’s state-of-the-art in-house laboratory, which allows for rapid processing and analysis of skin biopsies, significantly reducing the turnaround time for diagnoses. It emphasizes the collaborative approach between dermatopathologists and clinical dermatologists at Tareen Dermatology, ensuring seamless integration of clinical observations and histopathological findings.

Impact on Patient Care

The feature underscores the profound impact of Tareen Dermatology’s advanced dermatopathology techniques on patient care. Early detection and accurate diagnosis of skin conditions lead to improved prognosis and survival rates, personalized treatment plans, and enhanced patient confidence.

About Tareen Dermatology

Founded in Roseville, MN, in 2011 by nationally acclaimed board-certified dermatologist Dr. Mohiba Tareen, Tareen Dermatology is dedicated to providing cutting-edge and compassionate dermatologic care. The clinic has grown to six locations across Minnesota and Wisconsin, with a team of over 200 skilled professionals. Tareen Dermatology offers a comprehensive range of services, from medical dermatology to cosmetic treatments and surgical interventions, utilizing state-of-the-art technology and the latest advancements in dermatological science.

To read the full article, click here.

For more information about Tareen Dermatology, visit www.tareen dermatology.com.

Media Contact
Company Name: Tareen Dermatology
Email: Send Email
City: Roseville
State: Minnesota
Country: United States
Website: https://www.tareendermatology.com/

Advanced Renal Cell Carcinoma Pipeline 2024 | Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune

DelveInsight’s, “Advanced Renal Cell Carcinoma Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in Advanced Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Advanced Renal Cell Carcinoma Research. Learn more about our innovative pipeline today! @ Advanced Renal Cell Carcinoma Pipeline Outlook

Key Takeaways from the Advanced Renal Cell Carcinoma Pipeline Report

  • July 2024:- Ipsen- A Phase II, Multicentre, Open-label Study of Cabozantinib as 2nd Line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors. The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.
  • June 2024:- Bristol-Myers Squibb-  A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors. The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.
  • DelveInsight’s Advanced Renal Cell Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 60+ pipeline therapies for Advanced Renal Cell Carcinoma treatment.
  • The leading Advanced Renal Cell Carcinoma Companies such as Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, Molecure S.A., Daiichi Sankyo, Janux Therapeutics, MedImmune, Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Chongqing Precision Biotech Co., Ltd, Pfizer, Exelixis, BeiGene, Xencor, and others.
  • Promising Advanced Renal Cell Carcinoma Therapies such as KY1044, JK08, Pembrolizumab, Savolitinib, Sunitinib, TT-10, and others.

Stay informed about the cutting-edge advancements in Advanced Renal Cell Carcinoma treatments. Download for updates and be a part of the revolution in oncology care @ Advanced Renal Cell Carcinoma Clinical Trials Assessment

Advanced Renal Cell Carcinoma Emerging Drugs Profile

  • Belzutifan: Merck Sharp & Dohme

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2a). Belzutifan binds to HIF-2a, and in conditions of hypoxia or impairment of VHL protein function, belzutifan inhibits the HIF-2a-HIF-1ß interaction, leading to reduced transcription and expression of HIF-2a target genes. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of advanced renal cell carcinoma.

  • IPI-549: Infinity Pharmaceuticals

Eganelisib is a first-in-class, oral, once-daily, immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma). Selective PI3K-gamma inhibition represents a unique and potentially transformative approach within immuno-oncology (I/O), and IPI-549 has the potential to be a first-in-class therapy. Preclinical research conducted by Infinity and academic collaborators demonstrates that IPI-549 works by reprogramming key immune suppressive cells (called M2 macrophages or myeloid derived suppressor cells (MDSCs)) within the tumor microenvironment from a pro-tumor function to an anti-tumor function, decreasing immune suppression and increasing immune activation, ultimately leading to the activation and proliferation of T cells that can attack cancer cells. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of advanced renal cell carcinoma.

  • JANX008: Janux Therapeutics

JANX008 is an EGFR-TRACTr that is designed to overcome CRS and known on-target EGFR healthy tissue toxicities. Epidermal growth factor receptor (EGFR) is a clinically validated target highly expressed on many solid tumors that are being underserved by current therapies. JANX008 targets EGFR for the treatment of multiple solid cancers including, but not limited to, colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of advanced renal cell carcinoma.

Learn more about Advanced Renal Cell Carcinoma Drugs Opportunities in our groundbreaking Advanced Renal Cell Carcinoma research and development projects @ Advanced Renal Cell Carcinoma Unmet Needs

Advanced Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Advanced Renal Cell Carcinoma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Discover the latest advancements in Advanced Renal Cell Carcinoma treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Advanced Renal Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Advanced Renal Cell Carcinoma Pipeline Report

  • Coverage- Global
  • Advanced Renal Cell Carcinoma Companies- Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, Molecure S.A., Daiichi Sankyo, Janux Therapeutics, MedImmune, Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Chongqing Precision Biotech Co., Ltd, Pfizer, Exelixis, BeiGene, Xencor, and others.
  • Advanced Renal Cell Carcinoma Therapies- KY1044, JK08, Pembrolizumab, Savolitinib, Sunitinib, TT-10, and others.
  • Advanced Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Advanced Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Renal Cell Carcinoma pipeline on our website @ Advanced Renal Cell Carcinoma Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Renal Cell Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Renal Cell Carcinoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Belzutifan: Merck Sharp & Dohme
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. IPI-549: Infinity Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. JANX008: Janux Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Advanced Renal Cell Carcinoma Key Companies
  21. Advanced Renal Cell Carcinoma Key Products
  22. Advanced Renal Cell Carcinoma- Unmet Needs
  23. Advanced Renal Cell Carcinoma- Market Drivers and Barriers
  24. Advanced Renal Cell Carcinoma- Future Perspectives and Conclusion
  25. Advanced Renal Cell Carcinoma Analyst Views
  26. Advanced Renal Cell Carcinoma Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Renal Cell Carcinoma Pipeline 2024 | Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune

Advanced Gastric Carcinoma Pipeline 2024 | Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co., Ltd., Bristol-Myers Squibb, Hanmi Pharmaceuticals

DelveInsight’s, “Advanced Gastric Carcinoma Pipeline Insight, 2024,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Gastric Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Advanced Gastric Carcinoma Research. Learn more about our innovative pipeline today! @ Advanced Gastric Carcinoma Pipeline Outlook

Key Takeaways from the Advanced Gastric Carcinoma Pipeline Report

  • July 2024:- AstraZeneca- A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03).
  • July 2024:- LaNova Medicines Zhejiang Co., Ltd.- A Phase III, Open-Label, Multi Center, Randomized Study of LM-302 Versus Treatment of Physician’s Choice (TPC) in Patients With CLDN18.2-Positive, Locally Advanced or Metastatic Gastric(GC) and Gastroesophageal Junction(GEJ) Adenocarcinoma.
  • DelveInsight’s Advanced Gastric Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Gastric Carcinoma treatment.
  • The leading Advanced Gastric Carcinoma Companies such as Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co.,Ltd., Bristol-Myers Squibb, Hanmi Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd., Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Genentech, Innovent Biologics (Suzhou) Co. Ltd., Qilu Pharmaceutical Co., Ltd., NextCure, Inc., Chengdu Kanghong Biotech Co., Ltd., GeneQuantum Healthcare (Suzhou) Co., Ltd., Janssen Pharmaceutical K.K., Shanghai Miracogen Inc., Ambrx, Inc., Imugene Limited, Vedanta Biosciences, Inc., Celon Pharma SA, Bicycle Tx Limited, Seagen Inc., and others.
  • Promising Advanced Gastric Carcinoma Therapies such as MEDI4736, Bevacizumab, KN026, Zanidatamab, Tislelizumab, Trastuzumab, and others.

Stay informed about the cutting-edge advancements in Advanced Gastric Carcinoma treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Gastric Carcinoma Clinical Trials Assessment

Advanced Gastric Carcinoma Emerging Drugs Profile

  • Camrelizumab: Jiangsu Hengrui Medicine

Camrelizumab (formerly known as HR 301210, INCSHR 1210, SHR 1210) is a humanised high-affinity IgG4-kappa monoclonal antibody that targets the programmed cell death-1 receptor. Currently, it is in Phase III stage of clinical trial evaluation to treat advanced gastric or gastroesophageal junction adenocarcinoma.

  • Pamiparib: BeiGene

Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene’s investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies.

Learn more about Advanced Gastric Carcinoma Drugs Opportunities in our groundbreaking Advanced Gastric Carcinoma Research and development projects @ Advanced Gastric Carcinoma Unmet Needs

Advanced Gastric Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Advanced Gastric Carcinoma Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Discover the latest advancements in Advanced Gastric Carcinoma treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Advanced Gastric Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Advanced Gastric Carcinoma Pipeline Report

  • Coverage- Global
  • Advanced Gastric Carcinoma Companies- Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co.,Ltd., Bristol-Myers Squibb, Hanmi Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd., Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Genentech, Innovent Biologics (Suzhou) Co. Ltd., Qilu Pharmaceutical Co., Ltd., NextCure, Inc., Chengdu Kanghong Biotech Co., Ltd., GeneQuantum Healthcare (Suzhou) Co., Ltd., Janssen Pharmaceutical K.K., Shanghai Miracogen Inc., Ambrx, Inc., Imugene Limited, Vedanta Biosciences, Inc., Celon Pharma SA, Bicycle Tx Limited, Seagen Inc., and others.
  • Advanced Gastric Carcinoma Therapies- MEDI4736, Bevacizumab, KN026, Zanidatamab, Tislelizumab, Trastuzumab, and others.
  • Advanced Gastric Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Advanced Gastric Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Gastric Carcinoma Pipeline on our website @ Advanced Gastric Carcinoma Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Gastric Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Gastric Carcinoma – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Camrelizumab: Jiangsu Hengrui Medicine
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Pamiparib: BeiGene
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Venadaparib: Idience
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Advanced Gastric Carcinoma Key Companies
  21. Advanced Gastric Carcinoma Key Products
  22. Advanced Gastric Carcinoma- Unmet Needs
  23. Advanced Gastric Carcinoma- Market Drivers and Barriers
  24. Advanced Gastric Carcinoma- Future Perspectives and Conclusion
  25. Advanced Gastric Carcinoma Analyst Views
  26. Advanced Gastric Carcinoma Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Gastric Carcinoma Pipeline 2024 | Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co., Ltd., Bristol-Myers Squibb, Hanmi Pharmaceuticals

Electric Vehicle Market Forecast to Grow at 9.68% CAGR from 2024 to 2031 | SkyQuest Technology

“Skyquest Technology”
Electric Vehicle (EV) Market Size, Share, Growth Analysis, By Component(Onboard Chargers, Motors, Power Control Units, Battery Management Systems), By Propulsion(Battery Electric Vehicle, Plug-in Hybrid Electric Vehicle, Fuel Cell Electric Vehicle), By Vehicle Type(Two-Wheelers (Scooters, Motorcycles), Three-Wheelers, Passenger Cars (SUV), By Top Speed(Less Than 100 MPH, 100 to 125 MPH, More Than 125 MPH), By Region – Industry Forecast 2024-2031

Electric Vehicle (EV) Market size was valued at around USD 603.45 billion in 2022 and is expected to rise from USD 661.87 billion in 2023 to reach a value of USD 1386.08 Billion by 2031, at a CAGR of 9.68% over the forecast period (2024–2031).

In recent times, the demand for electric vehicle (EV) has significantly increased because of environment impact of traditional gasoline vehicles and the rise in fuel prices. The inclination of people towards battery-powered or hybrid automobiles is also driving the EV market. The popularity of BEVs has also grown among customers as these automobiles does not use conventional fuels like gasoline or diesel. Maintenance expense of EVs is much less than the conventional fuel-driven vehicles giving it an added advantage. As fossil fuel-driven vehicles are one of the primary reasons of air pollution and government bodies have enforced strict emission regulation on car manufacturers so that they reduce vehicle emissions. As electric vehicles operate on electric motor it needs constant supply of energy from batteries. There are different types of batteries used in the vehicles like lithium ion, molten salt, zinc-air, and various nickel-based designs. These batteries provide better function than the conventional vehicles with higher fuel economy, low carbon emission & maintenance, convenient charging at home, smooth drive, and minimized sound from engine. There are mainly three types of EVs like plug-in hybrid electric vehicles, battery electric vehicles, and fuel cell electric vehicle. Developments like solid-state batteries and enhancements in lithium-ion batteries are minimizing expenses and rising the energy density, making EVs more attractive to the customers.

Download a detailed overview:

https://www.skyquestt.com/sample-request/electric-vehicle-market 

Rise in Demand for Fuel-Efficientand Low-Emission Vehicles 

As gasoline is a fossil fuel it is non-renewable source of energy and can get exhausted in the future. Therefore, it has become crucial to support sustainable development and use other alternate sources of fuel. This consists of using the electric vehicle as it does nit use gas and are more affordable compared to the traditional vehicles. The electric vehicles can transform almost 50% of the electrical energy from the grid to power at the wheels but the gas-driven vehicles can just covert nearly 17% to 21% of the energy stored in the gasoline. The popularity of the fuel-efficient vehicles has also increased because of the increasing price in petrol and diesel. This is mainly due to the reducing fossil fuel reserves and the tendency of companies to earn maximum profit from the oil reserves. Today, there is a high demand for electrically powered vehicles due to the advancement of these fuel-efficient technologies, driving the market. 

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/electric-vehicle-market

Implementation of Autonomous Driving Features is Driving the Market Growth 

The integration of self-driving technologies is a major shift that is advancing the global electric vehicle market. The development of artificial intelligence and the combination of sensors in vehicles are enabling vehicle manufacturers to provide an advanced autonomous driving experience in the EVs. Market players like Tesla, Waymo, and General Motors’ Cruise division are few examples that have advanced this technology. There are many different types of features in these vehicles like the ADAS it has lane keeping assistance and adaptive cruise control. They also have conditional automation that can be used during particular situations. The combination of the two models EVs and autonomous technology can be extremely harmonious as they need similar components to get the best functioning vehicle. Moreover, the use of autonomous features in electric vehicle can enhance the and safety of the automobile. This is because AI has the ability to evaluate the best route to drive for minimizing energy waste and avoid accidents, boosting the growth of the electric vehicle market. 

Latest Headlines Related to the Electric Vehicle Market 

  • Tata Passenger Electric Mobility Ltd. and Shell India Markets Private Ltd. engaged into non-binding Memorandum of Understanding in April 2024. This will help them to launch public charging stations all over India.
  • In March 2024, Mercedes-Benz revealed their new electric vehicle EQA electric SUV in India that will be on road by July 2024.
  • In February 2023, bp announced their plans to invest $1 billion by 2030 into electric vehicle charging points all over the United States. With the investment Hertz and bp will bring fast charging infrastructure to Hertz locations.
  • In November 2022, Feintool engaged in a contract with a popular European OEM. With the contract the organization delivered stators and rotors to manufacture electric drives for electric vehicles. 

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/electric-vehicle-market

The global electric vehicle market is expanding on a large scale due to the factors like environmental impact, technological advancements, and government initiatives. The use of electric vehicles is increasing because many countries are trying to minimize the emission of green house gas in the atmosphere and rely less on fossil fuels. Many administrative bodies have also started offering subsidies and tax breaks so that more people purchase EVs. They are also investing on infrastructure to encourage technological advancement and implementation of charging stations. These have led to an increase in the supply and selection of electric vehicles from normal city cars, to luxurious SUVs, and even commercial trucks. With the development of batteries and increase in the public charging stations the electric vehicle market will witness a huge upsurge leading to its expansion.

Related Reports:

Edge Computing Market

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/electric-vehicle-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Electric Vehicle Market Forecast to Grow at 9.68% CAGR from 2024 to 2031 | SkyQuest Technology